{"protocolSection": {"identificationModule": {"nctId": "NCT00126438", "orgStudyIdInfo": {"id": "MBG312"}, "organization": {"fullName": "GE Healthcare", "class": "INDUSTRY"}, "briefTitle": "Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease", "officialTitle": "An Open-Label, Multicenter, Phase 3 Study Evaluating the Prognostic Usefulness of I-123 mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event"}, "statusModule": {"statusVerifiedDate": "2018-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-07"}, "primaryCompletionDateStruct": {"date": "2008-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-08-03", "studyFirstSubmitQcDate": "2005-08-03", "studyFirstPostDateStruct": {"date": "2005-08-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-06-30", "resultsFirstSubmitQcDate": "2017-03-24", "resultsFirstPostDateStruct": {"date": "2017-05-05", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-02-15", "lastUpdatePostDateStruct": {"date": "2018-03-14", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "GE Healthcare", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to predict cardiac outcome in subjects with heart failure and in comparison to subjects without cardiovascular disease."}, "conditionsModule": {"conditions": ["Heart Failure, Congestive"], "keywords": ["Heart Failure", "nuclear cardiology", "sympathetic innervation", "123I-mIBG"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "DIAGNOSTIC", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 515, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "123I-mIBG (meta-iodobenzylguanidine)", "type": "EXPERIMENTAL", "description": "Single dose", "interventionNames": ["Drug: 123I-mIBG (meta-iodobenzylguanidine)"]}], "interventions": [{"type": "DRUG", "name": "123I-mIBG (meta-iodobenzylguanidine)", "description": "Single Dose", "armGroupLabels": ["123I-mIBG (meta-iodobenzylguanidine)"], "otherNames": ["MIBG", "Iobenguane"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) Ratio", "description": "H/M ratio for 123I-mIBG uptake at 3 hours 50 minutes post administration was calculated by dividing the counts/pixel in the total myocardium region of interest (ROI) by the counts/pixel in the 7x7 pixel mediastinal ROI. Assessments were done by 3 independent readers. H/M ratios were categorized as 'Low' and 'High' based on being \\<1.6 or \u22651.6 respectively. The efficacy of 123I-mIBG was based on the prognostic value of the imaging data collected relative to time to adverse cardiac events. Data analysis to assess the relative hazard of an adverse cardiac event was performed only on HF participants categorized into 2 groups with H/M \\<1.6 and H/M \u22651.6 using a Cox proportional hazards model.", "timeFrame": "Approximately 24 months from the date of administration of 123I-mIBG"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Study subjects must be adults with an established diagnosis of heart failure (New York Heart Association Class II or III) and reduced left ventricular ejection fraction (LVEF) (\u2264 35%) or be healthy volunteers without heart disease.\n\nExclusion Criteria:\n\n* Healthy volunteers were not eligible if they had a history of diabetes mellitus, signs/symptoms of neurological disease (e.g., Parkinson's Disease, multiple system atrophy, Parkinsonian syndromes), or other diseases known to affect the sympathetic nervous system.\n* Subjects with New York Heart Association Class I or IV heart failure were not eligible.\n* Subjects were excluded if they had previously received 123I-mIBG or 131I-mIBG or participated in a clinical study involving investigational medicinal product or devices within 30 days.\n* Subjects that had a pacemaker or had received defibrillation, anti-tachycardia pacing or cardioversion to treat a previous arrhythmic event or had an ICD inserted within 30 days before study entry are not eligible.", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "John Strohmeyer", "affiliation": "GE Healthcare", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "GE Healthcare", "city": "Princeton", "state": "New Jersey", "zip": "08540", "country": "United States", "geoPoint": {"lat": 40.34872, "lon": -74.65905}}]}, "referencesModule": {"references": [{"pmid": "26666380", "type": "DERIVED", "citation": "Hachamovitch R, Nutter B, Menon V, Cerqueira MD. Predicting Risk Versus Predicting Potential Survival Benefit Using 123I-mIBG Imaging in Patients With Systolic Dysfunction Eligible for Implantable Cardiac Defibrillator Implantation: Analysis of Data From the Prospective ADMIRE-HF Study. Circ Cardiovasc Imaging. 2015 Dec;8(12):e003110. doi: 10.1161/CIRCIMAGING.114.003110."}, {"pmid": "21193691", "type": "DERIVED", "citation": "Gerson MC, Caldwell JH, Ananthasubramaniam K, Clements IP, Henzlova MJ, Amanullah A, Jacobson AF. Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circ Cardiovasc Imaging. 2011 Mar;4(2):87-93. doi: 10.1161/CIRCIMAGING.110.954784. Epub 2010 Dec 30."}, {"pmid": "20188504", "type": "DERIVED", "citation": "Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, Agostini D, Weiland F, Chandna H, Narula J; ADMIRE-HF Investigators. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010 May 18;55(20):2212-21. doi: 10.1016/j.jacc.2010.01.014. Epub 2010 Feb 25."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total 515 participants (453 Heart failure \\[HF\\] and 62 control) were enrolled in the study and received a single dose of investigational medicinal product (IMP) at 43 investigational centers.", "recruitmentDetails": "A total of 753 participants were screened, of whom 197 were screen failures due to inclusion/exclusion criteria; 24 withdrawn at participant's request; 2 withdrawn at investigator's request and 15 failed to complete all screening procedures.", "groups": [{"id": "FG000", "title": "AdreView - Heart Failure Group", "description": "AdreView (123I-mIBG \\[meta-iodobenzylguanidine\\]): 10 milliCurie (mCi) as a single intravenous dose."}, {"id": "FG001", "title": "Adreview - Control Group", "description": "AdreView (123I-mIBG): 10 mCi as a single intravenous dose."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "453"}, {"groupId": "FG001", "numSubjects": "62"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "419"}, {"groupId": "FG001", "numSubjects": "52"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "34"}, {"groupId": "FG001", "numSubjects": "10"}]}], "dropWithdraws": [{"type": "Withdrawal due to adverse event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "8"}, {"groupId": "FG001", "numSubjects": "8"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All participants who received IMP manufactured by the sponsor.", "groups": [{"id": "BG000", "title": "AdreView - Heart Failure", "description": "AdreView (123I-mIBG): 10 mCi as a single intravenous dose."}, {"id": "BG001", "title": "Adreview - Control Group", "description": "AdreView (123I-mIBG): 10 mCi as a single intravenous dose."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "453"}, {"groupId": "BG001", "value": "62"}, {"groupId": "BG002", "value": "515"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "61.5", "spread": "12.38"}, {"groupId": "BG001", "value": "58.8", "spread": "10.84"}, {"groupId": "BG002", "value": "61.2", "spread": "12.20"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "121"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "351"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "394"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Relationship Between the Occurrence of Adverse Cardiac Event and 123I-mIBG Uptake on Planar Scintigraphy Categorized as High or Low Heart to Mediastinum (H/M) Ratio", "description": "H/M ratio for 123I-mIBG uptake at 3 hours 50 minutes post administration was calculated by dividing the counts/pixel in the total myocardium region of interest (ROI) by the counts/pixel in the 7x7 pixel mediastinal ROI. Assessments were done by 3 independent readers. H/M ratios were categorized as 'Low' and 'High' based on being \\<1.6 or \u22651.6 respectively. The efficacy of 123I-mIBG was based on the prognostic value of the imaging data collected relative to time to adverse cardiac events. Data analysis to assess the relative hazard of an adverse cardiac event was performed only on HF participants categorized into 2 groups with H/M \\<1.6 and H/M \u22651.6 using a Cox proportional hazards model.", "populationDescription": "Primary efficacy population included 444 participants in HF group who received IMP and had a diagnostic (optimal/sub-optimal) 3 hour 50 minute planar image. Primary efficacy analysis was based on comparing only \"Adreview HF\" participants with low vs. high H/M and, therefore, did not include \"Adreview Control\" group.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "number of adverse cardiac events", "timeFrame": "Approximately 24 months from the date of administration of 123I-mIBG", "groups": [{"id": "OG000", "title": "AdreView-Heart Failure Group With High H/M Ratio", "description": "Participants in HF group who had high H/M ratio (more than or equal to 1.6)."}, {"id": "OG001", "title": "AdreView-Heart Failure Group With Low H/M Ratio", "description": "Participants in HF group who had low H/M ratio (less than 1.6)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "86"}, {"groupId": "OG001", "value": "358"}]}], "classes": [{"title": "Reader A (n=86, 355)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "111"}]}]}, {"title": "Reader B (n=86, 358)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "113"}]}]}, {"title": "Reader C (n=86, 352)", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "112"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis based on Reader A readings. Data analysis to assess the relative hazard of an adverse cardiac event was performed using a Cox proportional hazards model. Hazard (risk) of an event for a participant with low H/M at time \"t\" was expressed as Hl (t)/ Hh (t) = \u03a8, where Hl (t) and Hh (t) denote the hazard of an event at time t for participants with low H/M and high H/M respectively.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "At 0.025 level of significance.", "statisticalMethod": "Cox Proportional Hazards Model", "paramType": "Hazard Ratio (HR)", "paramValue": "0.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.18", "ciUpperLimit": "0.73"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis based on Reader B readings. Data analysis to assess the relative hazard of an adverse cardiac event was performed using a Cox proportional hazards model. Hazard (risk) of an event for a participant with low H/M at time \"t\" was expressed as Hl (t)/ Hh (t) = \u03a8, where Hl (t) and Hh (t) denote the hazard of an event at time t for participants with low H/M and high H/M respectively.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "At 0.025 level of significance.", "statisticalMethod": "Cox Proportional Hazards Model", "paramType": "Hazard Ratio (HR)", "paramValue": "0.36", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.18", "ciUpperLimit": "0.72"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Analysis based on Reader C readings. Data analysis to assess the relative hazard of an adverse cardiac event was performed using a Cox proportional hazards model. Hazard (risk) of an event for a participant with low H/M at time \"t\" was expressed as Hl (t)/ Hh (t) = \u03a8, where Hl (t) and Hh (t) denote the hazard of an event at time t for participants with low H/M and high H/M respectively.", "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.001", "pValueComment": "At 0.025 level of significance.", "statisticalMethod": "Cox Proportional Hazards Model", "paramType": "Hazard Ratio (HR)", "paramValue": "0.35", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.17", "ciUpperLimit": "0.72"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 30 hours after administration of the IMP.", "description": "Analysis was performed on safety population that included all participants who received a dose of IMP.", "eventGroups": [{"id": "EG000", "title": "AdreView - Heart Failure", "description": "AdreView (123I-mIBG): 10 mCi as a single intravenous dose.", "seriousNumAffected": 6, "seriousNumAtRisk": 453, "otherNumAffected": 0, "otherNumAtRisk": 453}, {"id": "EG001", "title": "Adreview - Control Group", "description": "AdreView (123I-mIBG): 10 mCi as a single intravenous dose.", "seriousNumAffected": 0, "seriousNumAtRisk": 62, "otherNumAffected": 0, "otherNumAtRisk": 62}], "seriousEvents": [{"term": "Atrioventricular Block", "organSystem": "Cardiac disorders", "sourceVocabulary": "11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}]}, {"term": "Cardiac Failure Congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}]}, {"term": "Bacteremia", "organSystem": "Infections and infestations", "sourceVocabulary": "11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}]}, {"term": "Chest Pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}]}, {"term": "Abdominal Pain", "organSystem": "Nervous system disorders", "sourceVocabulary": "11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}]}, {"term": "Syncope", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 453}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 62}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The only disclosure restriction on the PI and/or institution is that the Sponsor can review results communications prior to public release and can restrict communications regarding trial results for a period that is more than 30 days (publications/abstracts) but not to exceed 90 days (patent related issues) from the time submitted to the Sponsor to review. The PI may be asked to remove any Sponsor confidential information and/or delay publication to protect any proprietary information."}, "pointOfContact": {"title": "Jose Zubeldia, M.D.", "organization": "GE Healthcare", "email": "jose.zubeldia@ge.com", "phone": "011-44-1494-543137"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019797", "term": "3-Iodobenzylguanidine"}], "ancestors": [{"id": "D000000970", "term": "Antineoplastic Agents"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000019275", "term": "Radiopharmaceuticals"}], "browseLeaves": [{"id": "M21692", "name": "3-Iodobenzylguanidine", "asFound": "Zyban", "relevance": "HIGH"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M21258", "name": "Radiopharmaceuticals", "relevance": "LOW"}], "browseBranches": [{"abbrev": "ANeo", "name": "Antineoplastic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}